Preview

Опухоли женской репродуктивной системы

Расширенный поиск

РОЛЬ ФУЛВЕСТРАНТА В ЭНДОКРИННОЙ ТЕРАПИИ РАСПРОСТРАНЕННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.17650/1994-4098-2008-0-1-33-40

Полный текст:

Аннотация

РОЛЬ ФУЛВЕСТРАНТА В ЭНДОКРИННОЙ ТЕРАПИИ РАСПРОСТРАНЕННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Об авторах

J. F.R. Robertson
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


S. E. Come
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


S. E. Jones
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


L. Beex
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


M. Kaufmann
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


A. Makris
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


J. W.R. Nortier
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


K. Possinger
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


L.-E. Rutqvist
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Beth Israel Deaconess Medical Center, Boston, MA, USA; Charles A. Sammons Cancer Center, Dallas, TX, USA; University Medical Centre Nijmegen, Nijmegen, The Netherlands; Goethe University, Frankfurt, Germany; Academic Oncology Unit, Mount Vernon Hospital, Middlesex, UK; Leiden University Medical Center, Leiden, The Netherlands; Humboldt University Berlin, Berlin, Germany; Karolinska Institute, Stockholm, Sweden
Россия


Список литературы

1. Bertelli G., Pronzato P., Amoroso D. et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307—10.

2. Powles T.J., Hickish T., Kanis J.A. et al. Effect of tamoxifen on bone mineral den- sity measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78—84.

3. Fisher B., Constantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527—37.

4. Nabholtz J.M., Buzdar A., Pollak M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter ran- domized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758—67.

5. Bonneterre J., Thurlimann B., Robertson J.F. et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 post- menopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748—57.

6. Mouridsen H., Gershanovich M., Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post- menopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596—606.

7. Mouridsen H., Gershanovich M., Sun Y. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post- menopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101—9.

8. Dirix L., Piccart M.J., Lohrisch C. et al. Efficacy and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001;20:29A. [abstract 114].

9. Stenbygaard L.E., Herrstedt J., Thomsen J.F. et al. Toremifene and tamoxifen in advanced breast cancer — a double-blind cross-over trial. Breast Cancer Res Treat 1993;25:57—63.

10. Vogel C.L., Shemano I., Schoenfelder J. et al. Multicenter Phase II efficacy trial of toremifene in tamoxifenrefractory patients with advanced breast cancer. J Clin Oncol 1993;11:345—50.

11. Pyrhonen S., Valavaara R., Vuorinen J., Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994;29:223—8.

12. Pyrhonen S., Valavaara R., Modig H. et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a random- ized double-blind, the «Nordic» Phase III study. Br J Cancer 1997;76:270—7.

13. Pyrhonen S., Ellmen J., Vuorinen J. et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of anti-oestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999;56:133—43.

14. Holli K., Valavaara R., Blanco G. et al. Safety and efficacy results of a random- ized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000;18:3487—94.

15. Haarstad H., Gundersen S., Wist E. et al. Droloxifene — a new anti-estrogen. A phase II study in advanced breast can- cer. Acta Oncol 1992;31:425—8.

16. Buzdar A.U., Kau S., Hortobagyi G.N. et al. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1994;33:313—6.

17. Buzdar A., Hayes D., El-Khoudary A. et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002;73:161—75.

18. Coombes R.C., Haynes B.P., Dowsett M. et al. Idoxifene: a report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995;55:1070—4.

19. Johnston S.R. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001;7(Suppl 12):4376S—4377S.

20. Buzdar A., O’Shaughnessy J.A., Booser D.J. et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21:1007—14.

21. Buzdar A.U., Marcus C., Holmes F. et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988;45:344—5.

22. Cauley J.A., Norton L., Lippman M.E. et al. Continued breast cancer risk reduc- tion in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of ralox- ifene evaluation. Breast Cancer Res Treat 2001;65:125—34.

23. Dickler M.N., Norton L. The MORE trial: multiple outcomes for raloxifene evaluation — breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 2001;949:134—42.

24. Jubelirer S.J., Crowell Jr. E.B. The STAR (study of tamoxifen and ralox- ifene) trial in West Virginia. W V Med J 2000;96:602—4.

25. Ingle J.N. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133—6.

26. Peethambaram P.P., Ingle J.N., Suman V.J. et al. Randomized trial of diethylstilbestrol versus tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117—22.

27. Lшnning P.E., Taylor P.D., Anker G. et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111—6.

28. Hu X.F., Veroni M., De Luise M. et al. Circumvention of tamoxifen resist- ance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993;55:873—6.

29. DeFriend D.J., Howell A., Nicholson R.I. et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54:408—14.

30. Osborne C.K., Jarman M., McCague R. et al. The importance of tamoxifen metabolism in tamoxifen- stimulated breast tumor growth. Cancer Chemother Pharmacol 1994;34:89—95.

31. Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7(Suppl 12):4369s—75s.

32. Nicholson R.I., Gee J.M., Manning D.L. et al. Responses to pure anti-oestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resist- ant experimental and clinical breast can- cer. Ann N Y Acad Sci 1995;761:148—63.

33. Pink J.J., Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321—30.

34. Hutcheson I.R., Knowlden J.M., Barrow D. et al. The novel ER down-reg- ulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen- resistant MCF-7 breast cancer cells. Clin Cancer Res 2001;7:557. [abstract].

35. Hutcheson I.R., Knowlden J.M., Gee J.M.W. et al. Oestrogen receptor- mediated modulation of the EGFR/MAPK signalling pathway in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 2003;81:81—93.

36. Robertson J.F., Nicholson R.I., Bundred N.J. et al. Comparison of the short-term biological effects of 7a-[9- (4,4,5,5,5-pentafluoropentylsulfinyl)- nonyl]estra-1,3,5,(10)-triene-3,17b-diol (Faslodex) versus tamoxifen in post- menopausal women with primary breast cancer. Cancer Res 2001;61:6739—46.

37. Bundred N.J., Anderson E., Nicholson R.I. et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002;22:2317—9.

38. Osborne C.K., Pippen J., Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post- menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American Trial. J Clin Oncol 2002;20:3386—95.

39. Howell A., Robertson J.F., Quaresma Albano J. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmen-opausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396—403.

40. Robertson J.F., Osborne C.K., Howell A. et al. Fulvestrant versus anas- trozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229—38.

41. Mauriac L., Pippen J.E., Quaresma Albano J. et al. Fulvestrant (FaslodexTM) versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003;39:1228—33.

42. Vergote I., Robertson J.F.R., Kleeberg U. et al. Postmenopausal women who progress on fulvestrant («Faslodex») remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207—11.

43. Robertson J.F.R., Howell A., Abram P. et al. Fulvestrant versus tamox- ifen for the first-line treatment of advanced breast cancer (ABC) in post- menopausal women. Ann Oncol 2002;13(Suppl 5):46. [abstract 1640].

44. Howell A. Postmenopausal women with advanced breast cancer who progress on Fulvestrant or tamoxifen retain sensi- tivity to further endocrine therapies. Breast Cancer Res Treat 2002;76(Suppl 1):S72. [abstract 251].

45. Beyea S., Nicoll L.H. Back to basics. Administering i.m. injections the right way. Am J Nurs 1996;96:34—5.

46. Robertson J.F.R., Harrison M.P. Equivalent single-dose pharmacokinetics of two different dosing methods of pro- longed-release fulvestrant («Faslodex») in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 2003;52:346—8.

47. The ATAC Trialists’ Group. Arimidex, tamoxifen alone or in combi- nation. Anastrozole alone or in combina- tion with tamoxifen versus tamoxifen alone for adjuvant treatment of post- menopausal women with early breast cancer: first results of the ATAC ran- domised trial. Lancet 2002;359:2131—9.

48. Perey L., Thurlimann B., Hawle H. et al. Fulvestrant («Faslodex») as hor- monal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamox- ifen and aromatase inhibitors. Breast Cancer Res Treat 2002;76(Suppl 1):S72. [abstract 249].

49. Lшnning P.E., Bajetta E., Murray R. et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J Clin Oncol 2000;18:2234—44.

50. Kaufmann M., Bajetta E., Dirix L.Y. et al. Exemestane is superior to megestrol acetate after tamoxifen failure in post- menopausal women with advanced breast cancer: results if a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399—411.

51. Bertelli G., Garrone O., Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:60A. [abstract 238].

52. DeFriend D.J., Anderson E., Bell J. et al. Effects of 4-hydroxytamoxifen and a novel pure anti-oestrogen (ICI 182870) on the clonogeneic growth of human breast cancer cells in vitro. Br J Cancer 1994;70:204—11.

53. Nicholson R.I., Hutcheson I.R., Harper M.E. et al. Modulation of epider- mal growth factor receptor in endocrine- resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8:175—82.

54. Wakeling A., Nicholson R.I., Gee J.M. Prospects for combining hormonal and non-hormonal growth factor inhibition. Clin Cancer Res 2001;1(Suppl 12):4350S—55S.


Для цитирования:


Robertson J.F., Come S.E., Jones S.E., Beex L., Kaufmann M., Makris A., Nortier J.W., Possinger K., Rutqvist L. РОЛЬ ФУЛВЕСТРАНТА В ЭНДОКРИННОЙ ТЕРАПИИ РАСПРОСТРАНЕННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ. Опухоли женской репродуктивной системы. 2008;(1):33-40. https://doi.org/10.17650/1994-4098-2008-0-1-33-40

For citation:


Robertson J., Come S., Jones S., Beex L., Kaufmann M., Makris A., Nortier J., Possinger K., Rutqvist L. ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT. Tumors of female reproductive system. 2008;(1):33-40. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-1-33-40

Просмотров: 154


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)